(P-534) Similar Efficacy, Safety and CD4 T-cell Increase up to Week 96 Observed with Fostemsavir (FTR)-Based Regimens in the BRIGHTE Study and Dolutegravir (DTG)-Based Regimens in the VIKING-3 Study in Individuals with Multidrug-Resistant (MDR) HIV-1

Investigator
IRCCS San Raffaele Hospital and Vita-Salute San Raffaele University
Milano, Lombardia, Italy

ViiV Healthcare
Verona, Veneto, Italy

ViiV Healthcare
Verona, Veneto, Italy

Temple University
Chesterbrook, Pennsylvania, United States

GSK
Collegeville, Pennsylvania, United States

GlaxoSmithKline
Upper Providence, Pennsylvania, United States

Regional Medical Lead & US DEI Medical Engagement Lead
ViiV Healthcare
Durham, North Carolina, United States

Global medical lead
ViiV Healthcare, Brentford, UK
London, England, United Kingdom

ViiV Healthcare, Brentford, UK
Brentford, England, United Kingdom

Global Medical Lead
ViiV Healthcare, Brentford, UK
Brentford, England, United Kingdom